End-of-day quote
Korea S.E.
23:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
9,100
KRW
|
+1.00%
|
|
-0.66%
|
+0.33%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
123,682
|
126,612
|
115,658
|
138,068
|
Enterprise Value (EV)
1 |
160,400
|
169,245
|
155,754
|
197,683
|
P/E ratio
|
-9.5
x
|
209
x
|
94.5
x
|
34.5
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.65
x
|
1.93
x
|
1.33
x
|
1.46
x
|
EV / Revenue
|
3.43
x
|
2.57
x
|
1.79
x
|
2.1
x
|
EV / EBITDA
|
-17.5
x
|
58.3
x
|
17.6
x
|
40.5
x
|
EV / FCF
|
-35,707,082
x
|
-13,882,600
x
|
30,045,841
x
|
-6,416,045
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-0%
|
Price to Book
|
4.82
x
|
4.03
x
|
3.92
x
|
2.49
x
|
Nbr of stocks (in thousands)
|
13,629
|
14,226
|
14,226
|
15,222
|
Reference price
2 |
9,075
|
8,900
|
8,130
|
9,070
|
Announcement Date
|
22/03/21
|
22/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
60,362
|
46,717
|
65,741
|
87,087
|
94,335
|
EBITDA
1 |
10,181
|
-9,167
|
2,904
|
8,869
|
4,884
|
EBIT
1 |
7,629
|
-11,975
|
331.5
|
5,586
|
428.7
|
Operating Margin
|
12.64%
|
-25.63%
|
0.5%
|
6.41%
|
0.45%
|
Earnings before Tax (EBT)
1 |
2,225
|
-16,528
|
90.96
|
1,363
|
2,780
|
Net income
1 |
442.3
|
-13,252
|
606.7
|
1,229
|
3,835
|
Net margin
|
0.73%
|
-28.37%
|
0.92%
|
1.41%
|
4.07%
|
EPS
2 |
35.00
|
-955.0
|
42.64
|
86.00
|
262.9
|
Free Cash Flow
|
-
|
-4,492
|
-12,191
|
5,184
|
-30,811
|
FCF margin
|
-
|
-9.62%
|
-18.54%
|
5.95%
|
-32.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
58.45%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
421.81%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
22/03/21
|
22/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q3
|
---|
Net sales
|
15.05
|
12.64
|
22.09
|
23.84
|
23.59
|
17.57
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-1.421
|
-2.081
|
3.325
|
3.253
|
2.209
|
-3.2
|
-
|
Operating Margin
|
-9.44%
|
-16.47%
|
15.05%
|
13.64%
|
9.36%
|
-18.21%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-0.3805
|
-
|
-
|
-
|
-
|
-8.694
|
1.423
|
Net margin
|
-2.53%
|
-
|
-
|
-
|
-
|
-49.48%
|
-
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
96.00
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/11/21
|
11/03/22
|
16/05/22
|
12/08/22
|
11/11/22
|
13/03/23
|
10/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
30,471
|
36,718
|
42,633
|
40,097
|
59,615
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.993
x
|
-4.005
x
|
14.68
x
|
4.521
x
|
12.21
x
|
Free Cash Flow
|
-
|
-4,492
|
-12,191
|
5,184
|
-30,811
|
ROE (net income / shareholders' equity)
|
-
|
-43.6%
|
0.41%
|
0.94%
|
5.6%
|
ROA (Net income/ Total Assets)
|
-
|
-8.15%
|
0.2%
|
2.83%
|
0.17%
|
Assets
1 |
-
|
162,536
|
302,287
|
43,479
|
2,281,222
|
Book Value Per Share
2 |
40,895
|
1,882
|
2,211
|
2,073
|
3,644
|
Cash Flow per Share
2 |
6,539
|
297.0
|
426.0
|
554.0
|
1,127
|
Capex
1 |
1,746
|
4,985
|
8,280
|
4,967
|
26,349
|
Capex / Sales
|
2.89%
|
10.67%
|
12.59%
|
5.7%
|
27.93%
|
Announcement Date
|
22/03/21
|
22/03/21
|
22/03/22
|
21/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +0.33% | 102M | | +11.57% | 126B | | -4.96% | 11.27B | | +3.22% | 9.12B | | +38.90% | 5.61B | | -21.83% | 4.75B | | +8.74% | 3.45B | | -6.82% | 2.89B | | -13.32% | 2.07B | | -6.99% | 2.05B |
Medical Devices & Implants
|